Neurosciences Medicine

Neurosciences Medicine

From epilepsy to depression to Alzheimer’s, neurological conditions affect almost everyone. And people are desperately seeking solutions for themselves or someone they love. The Neurosciences Medicine (NSM) research program at the DCRI is dedicated to taking bold action to find these solutions.

Research Highlights

Study suggests digital treatment through a video game could improve attention in ADHD
  • Scientists from the DCRI designed and led a 20-site, 350-patient study to determine whether children ages 8 to 12 with ADHD benefited from the treatment in which users race through a course, dodge obstacles, and capture rewards to advance to the next level.

EEG Coordinating Center
  • DCRI’s coordinating center gathers all EEG data from sites around the world. Our faculty team of neurologists and epileptologists adjudicates and analyzes the data. We can serve as the CRO or work with your current CRO for this part of the study only.

Duke receives $12.5 million to study children with autism and ADHD
  • Duke researchers across disciplines — including psychology, psychiatry, neuroscience, engineering, computer science and public policy — will launch three major projects designed to improve early detection and treatment of children with autism and ADHD.

Comprehensive Experience in Neuroscience Research

We conduct industry- and government-funded clinical projects of all sizes.

Disorders
  • ADHD
  • Aggression
  • Alzheimer’s/dementias
  • Anxiety disorders
  • Autism
  • Bipolar disorders
  • Devices
  • Epilepsy
  • Major depression
  • Multiple sclerosis
  • Neurocognition
  • Neuromuscular disorders
  • Tourette syndrome/obsessive-compulsive disorder
  • Pain
  • Parkinson's disease
  • Schizophrenia
  • Sleep disorders
  • Substance abuse
  • Stroke
  • Traumatic brain injury
Trial/Study Experience
  • Early-phase PK/PD and POC trials, conducted in our onsite phase I unit
  • Game and device/sham-controlled trial design and conduct
  • Pediatrics (microdosing, PK)
  • Neurocritical care trials
  • Electroencephalography
  • Polysomnography
  • Nerve conduction studies and electromyography
  • Neuroimaging
  • Immune monitoring: mechanistic and predictive biomarkers
  • Translational studies
  • Large multisite trials
  • Full-service CRO activities (protocol design/development, data management, biostatistics, pharmacokinetics, site management/monitoring)

We Take Bold Steps in Neuroscience Medicine, Because Bold Solutions Are Needed

Driven by more than 40 psychiatry and neurology faculty, our program develops, conducts, and supports innovative phase I–IV clinical trials addressing neurological and psychiatric conditions for child, adolescent, adult, and geriatric patient populations.

Our Clinical Trials Experience

Innovations

  • Rapid-start site network for neurosciences trials
  • Biomarker development
  • Cognitive endpoint design and assessment in clinical trials
  • Control intervention development
  • FAST-FAIL trial methodology
  • Inpatient ICU trials (TBI)
  • Neuroimmunology biomarker imaging studies
  • Novel trial designs
  • RDOC-based research

Neurosciences Medicine Leadership

Daniel Laskowitz, MD, MHS, Director, Neurosciences Medicine

Daniel Laskowitz, MD, MHS, graduated from the Duke University School of Medicine. After completing his residency at Hospital of the University of Pennsylvania, he returned to Duke to complete his residency in cerebrovascular disease and neurocritical care. Laskowitz's research interests include exploring new therapeutic interventions in the clinical setting of stroke, intracranial hemorrhage, and closed head injury. He is committed to translational research, and has several active clinical research protocols designed to bring the research performed in the Multidisciplinary Research Laboratories to the clinical arena.

  • Danny Laskowitz Profile
  • Richard Keefe, PhD Neurosciences Profile
  • Scott Kollins Profile

stock photo

Connect With Us

On Twitter: @DCRI Neurosciences
Upcoming conferences

 

American Professional Society of ADHD and Related Disorders (APSARD)
Washington, D.C.
January 12–14, 2018